🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

The Third People's Hospital of Chengdu clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with The Third People's Hospital of Chengdu as lead sponsor. Synced 26 Sep 2026
6Current trials
3Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

The Third People's Hospital of Chengdu is the lead sponsor of 6 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Not applicable. The most-studied condition is Persistent Atrial Fibrillation.

ClinicalTrials.gov trials by status

  • Recruiting350%
  • Active, closed233%
  • By invitation117%

Trials by phase

  • Not applicable467%
  • Observational233%
01

Clinical trials sponsored by The Third People's Hospital of Chengdu

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
NCT06720766 · ClinicalTrials.gov ↗ · Fatty Liver Disease
Observational Recruiting 2023-10 China
Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices
NCT06652750 · ClinicalTrials.gov ↗ · Sick Sinus Syndrome, Atrioventricular Block, Second and Third Degree, Heart Failure
Not applicable Recruiting 2024-11 China
FIH Study of PFLotus in Persistent Atrial Fibrillation
NCT07301190 · ClinicalTrials.gov ↗ · Persistent Atrial Fibrillation
Not applicable Recruiting 2025-06 China
PRIor Myocardial Infarction Identification on Electrocardiogram
NCT06811194 · ClinicalTrials.gov ↗ · Prior Myocardial Infarction
Observational By invitation 2025-02 China
Using a Novel Balloon-shaped Large-Focal Pulsed Field Ablation Catheter in Persistent Atrial Fibrillation
NCT07294742 · ClinicalTrials.gov ↗ · Persistent Atrial Fibrillation
Not applicable Active, closed 2024-11 China
FIH of PFBalloon for PVI
NCT07320976 · ClinicalTrials.gov ↗ · Paroxysmal Atrial Fibrillation
Not applicable Active, closed 2024-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in The Third People's Hospital of Chengdu trials

7 conditions
Persistent Atrial Fibrillation2Fatty Liver Disease1Prior Myocardial Infarction1Paroxysmal Atrial Fibrillation1Sick Sinus Syndrome1Atrioventricular Block, Second and Third Degree1Heart Failure1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China63

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Persistent Atrial Fibrillation

SponsorTrials
Boston Scientific Corporation4
Medtronic Cardiac Ablation Solutions3
Xu Liu2

Sponsors with the most current trials registered for this condition.

05

Questions about The Third People's Hospital of Chengdu trials

How many clinical trials does The Third People's Hospital of Chengdu sponsor?

The Third People's Hospital of Chengdu is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The Third People's Hospital of Chengdu trials recruiting?

Yes. 3 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.